A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
OncoMed Pharmaceuticals, Inc.
Study ID
NCT03119428
Phase
PHASE1
Status
Terminated

Conditions

  • Locally Advanced Cancer
  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • OMP-313M32 — DRUG
    OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
  • Nivolumab — DRUG
    Human IgG4 anti-PD-1 monoclonal antibody

Study Details

The purpose of this study is to evaluate the safety and tolerability of OMP-31M32 as a single agent or in combination with nivolumab. OMP-313M32 is an experimental anti-TIGIT antibody that was developed to block TIGIT from binding PVR allowing the body's T-cells to destroy cancer cells.

Key Dates

Start date
May 2, 2017
Status verified
Aug 2020
Primary completion
May 15, 2019
Completion
May 15, 2019

Study Design

Enrollment
33 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: OMP-313M32
    Intravenous (in the vein) infusions of OMP-313M32 as a single agent
  • Experimental: OMP-313M32 and Nivolumab
    Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab

Primary Outcome Measure

Incidence of dose limiting toxicities (DLTs) [ Time Frame: Subjects will be assessed for DLTs through the end of the first cycle (Days 1-29) ]

Locations (5)

FacilityCityStateZIPSite coordinators
ScottsdaleScottsdaleArizona85258-
DurhamDurhamNorth Carolina27710-
OklahomaOklahoma CityOklahoma73104-
NashvilleNashvilleTennessee37203-
Salt Lake CitySalt Lake CityUtah84112-

Find similar trials in Scottsdale, AZ

By research site
Scottsdale· Scottsdale, AZDurham· Durham, NCOklahoma· Oklahoma City, OKNashville· Nashville, TNSalt Lake City· Salt Lake City, UT

Related Studies